Amgen (AMGN) DIvidends Date & History

Key Takeaways

• Amgen Inc. (AMGN) offers a current dividend yield of approximately 2.63% to 2.67%.
• The company pays dividends quarterly at a rate of $2.52 per share recently, for an annualized total near $10.08.
• Amgen has maintained 14 consecutive years of dividend increases.
• Payout ratio stands around 61% to 66%, supported by strong free cash flow.
• The dividend profile positions Amgen as a moderate-yield dividend growth stock in the healthcare sector.
• Relative to peers, the yield is competitive but not the highest in the industry.

Dividend Overview

Amgen Inc. (AMGN) follows a quarterly dividend payment schedule. The most recent quarterly dividend is $2.52 per share, contributing to an annualized payout of about $10.08. With the stock trading near $377, this translates to a dividend yield in the 2.63% to 2.67% range. The company began paying dividends in 2011 and has established itself as a dividend growth stock rather than a high-yield name. Its policy emphasizes consistent increases tied to earnings and cash flow generation, appealing to investors seeking moderate income with growth potential in the biotechnology space.

Dividend History and Growth

Amgen has raised its dividend annually for 14 consecutive years. Quarterly payments have grown steadily from $0.28 in 2011 to the current $2.52 level. Recent increases include a 5.88% hike in early 2026 and similar adjustments in prior years, such as 5.78% in 2025 and 5.63% in 2024. The company maintains a disciplined approach, aligning dividend growth with overall financial performance while preserving capital for research and development.

Dividend Sustainability and Payout Ratio

The payout ratio of approximately 61% to 66% indicates sustainable dividend coverage from earnings. Free cash flow provides additional support, with historical coverage ratios remaining healthy. Amgen maintains a solid balance sheet with manageable debt levels relative to its cash-generating ability in the pharmaceutical industry. This financial stability suggests the dividend is well-covered and likely to continue without strain under normal operating conditions.

Dividend Compared to Industry Peers

Within the healthcare sector, Amgen's yield of around 2.63% compares favorably to some peers like Johnson & Johnson at 1.99% and Eli Lilly at 0.6%, but trails higher-yielding names such as Pfizer at 6.2% and Bristol-Myers Squibb at 3.94%. Its payout ratio is more conservative than several competitors, reflecting a balanced approach that prioritizes dividend growth alongside reinvestment in its pipeline.

AI Screener

AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking dividend opportunities may explore the platform for tailored insights.

Is This Stock Attractive for Dividend Investors?

Amgen Inc. (AMGN) may appeal to dividend growth investors seeking a moderate yield combined with a track record of annual increases. Its quarterly payments and reasonable payout ratio suit those prioritizing consistency over high current income. Long-term investors in the healthcare sector could find the combination of dividend growth and underlying business stability attractive for portfolio income generation. Conservative income investors might view it as a balanced holding, though the yield is not the highest available in the industry. The stock fits profiles focused on sustainable payouts rather than maximum yield.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations